Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Prothena Corporation plcNASDAQ: PRTA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $918K rose 311.7% year over year, ahead of the +156.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +70.7% a year.
Context
- Depreciation & amortization amounted to 38.2% of revenue in FY2025, up 37.6 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +311.7% holds above the trailing-twelve-month pace of +156.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.7M USD
- Year-over-year change
- +314.6%
- 4-year CAGR
- +35.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.7M | +314.6% |
| FY2024 | 2024-12-31 | 893K | -3.8% |
| FY2023 | 2023-12-31 | 928K | +24.7% |
| FY2022 | 2022-12-31 | 744K | -33.3% |
| FY2021 | 2021-12-31 | 1.12M | — |
Depreciation & Amortization vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +156.8% is the highest of 8, against a peer median of +3.4%.
- Depreciation & amortization amounts to 4.0% of revenue for PRTA, versus a peer median of 43.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $842.9M USD | +13.2% | +14.6% | 8.5% | |
| LTM Jun 2026 | $13.14M USD | +17.5% | +12.6% | 364.7% | |
| LTM Mar 2026 | $3.06M USD | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $2.31M USD | +156.8% | +70.7% | 4.0% | |
| LTM Mar 2026 | CHF 1.61M CHF | -27.3% | +2.0% | 43.6% | |
| LTM Mar 2026 | $251K USD | -0.8% | -1.0% | — | |
| LTM Mar 2026 | $185K USD | +3.4% | +2.9% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K USD | -90.6% | -29.5% | — |
| LTM Dec 2025 | $0 USD | — | — | — | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| Peer median (excluding PRTA) | — | +3.4% | +2.9% | 43.6% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.7M |
| Gross Profit | 200.58M | 53.91M | 91.37M | 135.16M | 5.98M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 61.8% |
| Research & Development | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M |
| Selling, General & Admin | 46.32M | 49.9M | 61.84M | 67.2M | 59.39M |
| Operating Expenses | 128.6M | 185.46M | 282.41M | 289.72M | 190.54M |
| Depreciation & Amortization | 1.12M | 744K | 928K | 893K | 3.7M |
| EBITDA | 73.04M | (124.86M) | (159.55M) | (128.04M) | (197.13M) |
| EBITDA Margin | 36.4% | -231.6% | -174.6% | -94.7% | -2035.6% |
| Operating Income | 71.98M | (131.56M) | (191.04M) | (154.56M) | (184.56M) |
| Operating Margin | 35.9% | -244.1% | -209.1% | -114.4% | -1905.8% |
| Interest Income | 42K | 6.35M | 31.01M | 25.82M | 14.14M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (54K) | 5.95M | 30.56M | 25.63M | (16.27M) |
| Income Before Tax | 71.92M | (125.61M) | (160.48M) | (128.93M) | (200.83M) |
| Pre-Tax Margin | 35.9% | -233.0% | -175.6% | -95.4% | -2073.8% |
| Income Tax Expense | 4.95M | (8.66M) | (13.45M) | (6.62M) | 43.26M |
| Net Income | 66.98M | (116.95M) | (147.03M) | (122.31M) | (244.09M) |
| Net Margin | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
| EPS (Basic) | 1.51 | (2.47) | (2.76) | (2.27) | (4.53) |
| EPS (Diluted) | 1.38 | (2.47) | (2.76) | (2.27) | (4.53) |
| Weighted Avg Shares | 44.23M | 47.37M | 53.22M | 53.77M | 53.83M |
| Weighted Avg Shares (Diluted) | 48.46M | 47.37M | 53.22M | 53.77M | 53.83M |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.